DYAI earnings analysis
What we found in DYAI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Dyadic reported Q2 revenue of $961,138 and EPS of $(0.06), missing consensus revenue of $1,021,592 and EPS of $(0.04). Grant revenue increased $334,071 to $837,252, but cost of revenue rose 60.4% to $984,165, producing an approximate 2.4% negative gross margin. The most material development in the 10-Q is management’s conclusion that substantial doubt exists regarding the company’s ability to continue as a going concern, alongside renewed disclosure of funding dilution and Nasdaq delisting risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue missed consensus by 5.9%
- Q2 revenue was $961,138, while consensus was $1,021,592, a shortfall of $60,454, or 5.9%.
- Grant revenue provided support
- Grant revenue increased $334,071 to $837,252, partially offsetting weaker collaboration revenue.
- Cost inflation drove gross loss
- Cost of revenue rose 60.4% to $984,165, exceeding revenue of $961,138 and producing an approximate negative gross margin of 2.4%.
- EPS missed consensus
- Reported EPS was $(0.06), versus consensus EPS of $(0.04), a $0.02-per-share miss.
- Going-concern disclosure remains material
- Management concluded that substantial doubt exists regarding the company’s ability to continue as a going concern as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial doubt over going concern
- The company stated there is substantial doubt about its ability to continue as a going concern. Management warned that failure of mitigation efforts could force it to limit operations or be unable to continue as a going concern.
- Funding and dilution risk
- Potential mitigation includes a capital raise that could be highly dilutive, with no assurance of favorable terms. The company also stated there is no guarantee that grant applications will be approved or that noteholders will modify, exchange, or extend the Convertible Notes.
- Nasdaq compliance and delisting risk
- Although the company regained compliance, it could again violate Nasdaq’s $1.00 minimum bid-price rule or the $2.5 million shareholders’ equity, $35 million market-value-of-listed-securities, or $500,000 net-income continued-listing standards.
- Reverse-split and liquidity risk
- If the stock closes below the $1.00 minimum bid price for 30 consecutive business days, the Board may consider a reverse stock split. A reverse split could reduce liquidity if the share price does not increase afterward.
- Revenue insufficient to cover direct costs
- Q2 cost of revenue was $984,165 against revenue of $961,138, resulting in a gross loss of approximately $23,027 and indicating limited operating leverage at the current revenue level.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.06
- Gross margin
- -2.4%
- Segment
- Grant revenue: $837,252, up $334,071 versus the prior-year period
- Segment
- Collaboration revenue: approximately $123,886, inferred as total revenue of $961,138 less grant revenue of $837,252
What they said about what is next.
No quantitative forward guidance was provided in the filing; management instead disclosed substantial doubt about continuing as a going concern.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Dyadic International reported a significant increase in revenue for Q4 2026, totaling $1,110,956, which is a 182.3% increase compared to $393,572 in Q4 2025. However, the net loss narrowed slightly to $(1,954,683) from…
- 10-K · April 30, 2026
- Dyadic International reported significant challenges in Q4 2025, posting revenues of $565,526 against estimates of $1,406,004, leading to an EPS of $(0.06), below expectations of $(0.04). The company is grappling with a…
- 10-K · March 25, 2026
- Dyadic’s 2025 Form 10-K frames a strategic shift from a development-stage platform company toward commercializing animal‑free recombinant proteins and enzymes via its Dapibus™ and C1 production platforms (the filing…
- 10-Q · May 14, 2025
- Dyadic reported Q1 2025 revenue of $393,572, up $58,955 or 17.6% versus Q1 2024, driven by a new $210,472 of grant revenue while research & development revenue declined. Net loss was $2,027,579 (EPS –$0.07), roughly…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DYAI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever